New hope for recurrent ovarian cancer: targeted drug combo enters human trials
NCT ID NCT06843447
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests a new drug called raludotatug deruxtecan (R-DXd) for people with a fast-growing type of ovarian cancer that has returned after standard chemotherapy. R-DXd is an antibody drug conjugate that targets and destroys cancer cells. The study will check safety and how well the cancer responds when R-DXd is given alone or with other experimental drugs. About 280 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barts Health NHS Trust ( Site 0401)
RECRUITINGLondon, London, City of, E1 1RD, United Kingdom
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 0301)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario 12 de Octubre ( Site 0304)
RECRUITINGMadrid, 28041, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
RECRUITINGMadrid, 28040, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0010)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-••••
-
Memorial Sloan Kettering Cancer Center ( Site 0003)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 0202)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Royal Marsden Hospital ( Site 0402)
RECRUITINGFulham, England, SW3 6JJ, United Kingdom
Contact Phone: •••-•••-••••
-
START Mountain Region ( Site 0008)
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-••••
-
Shaare Zedek Medical Center ( Site 0201)
RECRUITINGJerusalem, 9103102, Israel
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0200)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
The Royal Marsden NHS Foundation Trust. ( Site 0403)
RECRUITINGSutton, England, SM2 5PT, United Kingdom
Contact Phone: •••-•••-••••
-
The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
RECRUITINGLouisville, Kentucky, 40202, United States
Contact Phone: •••-•••-••••
-
University of Virginia Health System ( Site 0011)
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.